Rordorf Roberto
Arrhythmias and Electrophysiology Unit, Policlinico San Matteo Foundation, Pavia, Italy.
Arrhythm Electrophysiol Rev. 2022 Apr;11. doi: 10.15420/aer.2022.11.S1.
This review sets out the key evidence comparing subcutaneous ICDs (S-ICDs) and transvenous ICDs and uses it to empower clinical cardiologists and those who implant ICDs to make optimum patient selections for S-ICD use. The evidence demonstrates that clinical trials performed until recently have proven the performance of S-ICDs. However, the latest data now available from the ATLAS randomised controlled trial have added new insights to this body of evidence. ATLAS demonstrates the superiority of S-ICDs over transvenous ICDs regarding lead-related complications, findings that point to promising opportunities for patients who are at risk of sudden cardiac death.
本综述阐述了比较皮下植入式心律转复除颤器（S-ICD）和经静脉植入式心律转复除颤器的关键证据，并利用这些证据助力临床心脏病专家以及植入心律转复除颤器的人员为S-ICD的使用做出最佳患者选择。证据表明，直到最近进行的临床试验已证实了S-ICD的性能。然而，目前可从ATLAS随机对照试验获得的最新数据为这一证据体系增添了新见解。ATLAS证明了S-ICD在与导线相关的并发症方面优于经静脉植入式心律转复除颤器，这些发现为有心脏性猝死风险的患者指明了充满希望的机会。
